rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FHTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Foghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat Estimates
      Nov 9Yahoo FinanceFHTX
      Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
      Nov 9Yahoo FinanceFHTX
      Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November

      WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference. Guggenheim Third Annual Healthcare Innovation Conference Fireside Chat: Tues

      Nov 3Yahoo FinanceFHTX
      Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
      Oct 22Yahoo FinanceFHTXLLY
      Evercore ISI Downgrades Foghorn Therapeutics to In Line, $3 Price Target
      Oct 13Yahoo FinanceFHTX
      Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
      Oct 13Investing.comFHTX
      Foghorn: Downgrade "Sell" Eli Lilly Exit FHD-909 And Shift To Preclinical Assets

      Foghorn Therapeutics downgraded to Sell after SMARCA2/Lilly exit; cash runway to 2029 but no catalysts until 2027. Read more on FHTX stock here.

      Oct 6Seeking AlphaFHTXLLY
      Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

      Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailFHTX
      Why is Foghorn Therapeutics stock plunging today?
      Oct 2Investing.comFHTX
      Foghorn Therapeutics Shares Fall After Wedbush Downgrade

      Foghorn Therapeutics (FHTX) shares fell 29% in Friday trading after Wedbush downgraded the stock to

      Oct 2Yahoo FinanceFHTX
      Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ)

      Foghorn Therapeutics (FHTX) stock slips after Eli Lilly (LLY) ends collaboration, prompting TD Cowen and others to downgrade the company. Read more here.

      Oct 2Seeking AlphaFHTXLLY
      Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal

      The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects

      Oct 2Yahoo FinanceFHTXLLY
      Wedbush cuts Foghorn Therapeutics stock rating on drug setback
      Oct 2Investing.comFHTX
      Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt
      Oct 2Investing.comFHTX
      Guggenheim cuts Foghorn Therapeutics price target on drug setback
      Oct 2Investing.comFHTX
      Wedbush Downgrades Foghorn Therapeutics to Neutral From Outperform, Cuts Price Target to $2 From $10
      Oct 2Yahoo FinanceFHTX
      TD Cowen Downgrades Foghorn Therapeutics to Hold From Buy

      Foghorn Therapeutics (FHTX) has an average rating of overweight and mean price target of $8.86, acco

      Oct 2Yahoo FinanceFHTX
      BTIG Downgrades Foghorn Therapeutics to Neutral From Buy

      Foghorn Therapeutics (FHTX) has an average rating of overweight and mean price target of $8.86, acco

      Oct 2Yahoo FinanceFHTX
      FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
      Oct 2Yahoo FinanceFHTX
      Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt
      Oct 1Investing.comFHTX
      Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation
      Oct 1Investing.comFHTX
      Stifel cuts Foghorn Therapeutics stock price target on pipeline shift
      Oct 1Investing.comFHTX
      Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

      Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY4050784), Foghorn and Eli Lilly & Co. (NYSE:LLY) will not advance the program into clinical development expansion. The companies also will not advance their Selective SMARCA2 degrader program and do not

      Oct 1Yahoo FinanceFHTXLLY
      Why Is Foghorn Therapeutics Stock Tumbling Today? - Foghorn Therapeutics (NASDAQ:FHTX)

      Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.

      Oct 1BenzingaFHTXLLY
      Lilly, Foghorn part ways; Wave’s FDA-approved plans

      The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

      Oct 1Yahoo FinanceFHTX
      Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review

      Foghorn and Lilly will end further collaboration activities after FHD-909 failed to demonstrate sufficient efficacy, while Foghorn cuts its workforce by approximately 40% and extends its cash runway into the second half of 2029. Key Investor TakeawaysFoghorn Therapeutics (NASDAQ:FHTX) and Lilly decided not to advance FHD-909 into clinical expansion following a review of Phase 1 dose-escalation data.

      Oct 1Yahoo FinanceFHTX
      FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?

      Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.

      Oct 1Yahoo FinanceFHTX
      Why is Foghorn Therapeutics stock plummeting today?
      Oct 1Investing.comFHTX
      Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
      Oct 1Yahoo FinanceFHTX
      Foghorn ends FHD-909 program, cuts 40% of workforce
      Oct 1Investing.comFHTX
      Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
      Oct 1Barron'sFHTXLLY
      Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ)

      Foghorn Therapeutics (FHTX) stock plunges as Lilly (LLY) ends a 2021 collaboration resulting in nearly a 40% workforce reduction. Read more here.

      Oct 1Seeking AlphaFHTXLLY
      Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

      Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.,

      Oct 1Yahoo FinanceFHTX
      12 Health Care Stocks Moving In Thursday's Intraday Session - Nexalin Technology (NASDAQ:NXL), Stablecoin
      Oct 1BenzingaFHTXNXL
      Citizens reiterates Foghorn Therapeutics stock rating on trial data
      Sep 17Investing.comFHTX
      Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
      Sep 16Yahoo FinanceFHTX
      TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
      Sep 9Yahoo FinanceDNTHFHTX
      B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX)

      Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailFHTX
      Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

      The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Aug 26Yahoo FinanceFHTX

      This is the newest page. Registered accounts read further back.